Photo from wikipedia
Abstract: The advent of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by… Click to show full abstract
Abstract: The advent of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan‐American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy.
Journal Title: Asia-Pacific Journal of Ophthalmology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!